A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms (NCT06223880)
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Site — Bellflower, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Clinical Research Site — Bellflower, California
- Clinical Research Site — Lafayette, California
- Clinical Research Site — Oceanside, California
- Clinical Research Site — Redlands, California
- Clinical Research Site — Riverside, California
- Clinical Research Site — San Diego, California
- Clinical Research Site — Upland, California
- Clinical Research Site — Brandon, Florida
- Clinical Research Site — Doral, Florida
- Clinical Research Site — Hialeah, Florida
- Clinical Research Site — Jacksonville, Florida
- Clinical Research Site — Miami, Florida
- Clinical Research Site — Orlando, Florida
- Clinical Research Site — Orlando, Florida
- Clinical Research Site — Orlando, Florida
- Clinical Research Site — Atlanta, Georgia
- Clinical Research Site — Chicago, Illinois
- Clinical Research Site — Overland Park, Kansas
- Clinical Research Site — New Orleans, Louisiana
- Clinical Research Site — Boston, Massachusetts
- Clinical Research Site — Saint Charles, Missouri
- Clinical Research Site — Las Vegas, Nevada
- Clinical Research Site — Cherry Hill, New Jersey
- Clinical Research Site — Toms River, New Jersey
- Clinical Research Site — Brooklyn, New York
📞 Contact the Study Coordinator
Phone: (212) 332-5061
Email: axs-05-mdd-401@axsome.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Major Depressive Disorder
- Fisher Wallace Neurostimulation & Depression Study — New York, New York
- Study to Assess the Safety and Effectiveness of NMRA-335140-501 — Huntsville, Alabama
- Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD) — Los Angeles, California
- Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin — Toronto, Ontario
- Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder — West Haven, Connecticut
- Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans — West Haven, Connecticut
Explore by condition: All Major Depressive Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.